Companies / Mereo BioPharma Group plc

Mereo BioPharma Group plc

Nasdaq: MREOCIK 1719714LONDON

Financials · FY2025

Revenue$500.0K
Net income$-41.88M
Total debt—
Cash$30.12M
Diluted EPS$-0.05
Shares outstanding798.5M

Ownership

798.5M shares outstanding · as of Aug 7, 2026
8.2%Institutions
Ownership
Institutions8.23%65,694,437
Public float91.77%732,760,427

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 13

View all →
Insider% of sharesShares
Bender JeremyDirector
——
Ekblom AndersDirector
——
Fox Christine AnnChief Financial Officer
——
Hughes-Wilson AlexandraFormerSee Remarks
——
Jacquet PierreDirector
——
Jenkins AnnalisaDirector
——
Lewicki John A.FormerChief Scientific Officer
——
Pakianathan DeepikaDirector
——
Scots-Knight DeniseCEOChief Executive Officer · Director
——
Sermon CharlesGeneral Counsel
——

Institutional holders 74

View all →
HolderValue% of shares
Rubric Capital Management LP$6.38M1.92%
683 Capital Management, LLC$6.26M1.88%
EcoR1 Capital, LLC$3.27M0.98%
Schonfeld Strategic Advisors LLC$2.54M0.76%
Millennium Management LLC$1.17M0.45%
Tejara Capital Ltd$899.9K0.27%
Logos Global Management LP$770.9K0.23%
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC$735.4K0.22%
Monaco Asset Management SAM$660.6K0.20%
UBS Group AG$650.1K0.20%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Feb 26, 2026Jacquet Pierre
Director
GrantDeferred Restricted Stock Units—+107K
106,848
0.01% of shares
low
Feb 26, 2026Jacquet Pierre
Director
GrantShare Options (Right to buy)—+66K
66,000
<0.01% of shares
low
Feb 26, 2026Bender Jeremy
Director
GrantDeferred Restricted Stock Units—+118K
117,533
0.01% of shares
low
Feb 26, 2026Bender Jeremy
Director
GrantShare Options (Right to buy)—+66K
66,000
<0.01% of shares
low
Feb 26, 2026Jenkins Annalisa
Director
GrantDeferred Restricted Stock Units—+107K
106,848
0.01% of shares
low
Feb 26, 2026Jenkins Annalisa
Director
GrantShare Options (Right to buy)—+66K
66,000
<0.01% of shares
low
Feb 26, 2026Yoskowitz Marc J
Director
GrantDeferred Restricted Stock Units—+96K
96,163
0.01% of shares
low
Feb 26, 2026Yoskowitz Marc J
Director
GrantShare Options (Right to buy)—+66K
66,000
<0.01% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Janus Henderson Group PLCPassive13G/A———
683 Capital Management, LLCPassive13G———
EcoR1 Capital, LLCPassive13G———
Frazier Life Sciences Public Fund, L.P.Passive13G/A———
Northpond Ventures, LPPassive13G/A———

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
MREOADREquity589492107BBG00KFWZC67